Increased mortality in postmenopausal women with serum CA125 elevation

Area of Science:

• Oncology
• Biomarker Research
• Geriatric Medicine

Background:

• Serum CA125 is a biomarker used in ovarian cancer (OC) monitoring and detection.
• Elevated CA125 levels can be associated with various conditions, including physiological, benign, and malignant ones.
• The prognostic significance of CA125 elevation in asymptomatic individuals requires further elucidation.

Purpose of the Study:

• To investigate the prognostic implications of elevated serum CA125 levels in asymptomatic postmenopausal women.
• To determine if CA125 elevation predicts mortality risk independently of other factors.
• To assess the association between CA125 levels and all-cause mortality.

Main Methods:

• A cohort of 771 asymptomatic postmenopausal women with elevated serum CA125 (>=30 U/ml) was identified from an OC screening trial.
• A control group of 771 women with normal CA125 levels was selected.
• Survival analysis, including univariate (log-rank test) and multivariate (logistic model) analyses, was performed, with follow-up from the initial CA125 elevation.

Main Results:

• The group with elevated CA125 showed significantly higher mortality rates compared to the control group (RR = 2.76, P < 0.0001).
• This increased mortality risk persisted even after excluding women with pre-existing morbid conditions (RR = 2.4, P = 0.0001).
• Multivariate analysis identified CA125 elevation, age over 60, and a history of cancer as independent predictors of poor prognosis.

Conclusions:

• Elevated serum CA125 in asymptomatic postmenopausal women is linked to a substantially increased risk of all-cause mortality within 5 years.
• These findings suggest CA125 elevation may serve as a prognostic indicator in this population.
• The results have potential implications for the clinical management and follow-up of asymptomatic postmenopausal women with elevated CA125 levels.